Exact Sciences, Takeda & more — 4 GI company key notes

Here are four updates on GI companies from the past week.

According to Genome Web, Exact Sciences closed a revolving loan for $15 million and a non-revolving loan for $25.6 million, intended for their new headquarters project.

Senzime was awarded a CE Mark for its OnZurf probe, a tool for gastrointestinal tract surgical procedures.

The European Medicines Agency issued a positive opinion on Takeda and TiGenix's Cx601, a complex perianal fistulas treatment for adults with non-active/mildly active luminal Crohn's disease.

More articles on gastroenterology: 
Exact Sciences secures $40.6M in financing — 3 insights
GI leader to know: Dr. Philip Nagel of Gastroenterology & Internal Medicine Specialists
Stock market week-in-review for 5 large GI companies — Dec. 11-15

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months